Skip to main content
NCBI home page
Molecular and Cellular Biology logoLink to Molecular and Cellular Biology
. 1994 Jun;14(6):4193–4202. doi: 10.1128/mcb.14.6.4193

Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.

G C Prendergast 1, J P Davide 1, S J deSolms 1, E A Giuliani 1, S L Graham 1, J B Gibbs 1, A Oliff 1, N E Kohl 1
PMCID: PMC358785  PMID: 8196657

Abstract

A potent and specific small molecule inhibitor of farnesyl-protein transferase, L-739,749, caused rapid morphological reversion and growth inhibition of ras-transformed fibroblasts (Rat1/ras cells). Morphological reversion occurred within 18 h of L-739,749 addition. The reverted phenotype was stable for several days in the absence of inhibitor before the transformed phenotype reappeared. Cell enlargement and actin stress fiber formation accompanied treatment of both Rat1/ras and normal Rat1 cells. Significantly, inhibition of Ras processing did not correlate with the initiation or maintenance of the reverted phenotype. While a single treatment with L-739,749 was sufficient to morphologically revert Rat1/ras cells, repetitive inhibitor treatment was required to significantly reduce cell growth rate. Thus, the effects of L-739,749 on transformed cell morphology and cytoskeletal actin organization could be separated from effects on cell growth, depending on whether exposure to a farnesyl-protein transferase inhibitor was transient or repetitive. In contrast, L-739,749 had no effect on the growth, morphology, or actin organization of v-raf-transformed cells. Taken together, the results suggest that the mechanism of morphological reversion is complex and may involve farnesylated proteins that control the organization of cytoskeletal actin.

Full text

PDF
4193

Images in this article

4195Image
on p.4195
4196Image
on p.4196
4197Image
on p.4197
4199Image
on p.4199
4199Image
on p.4199

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamson P., Marshall C. J., Hall A., Tilbrook P. A. Post-translational modifications of p21rho proteins. J Biol Chem. 1992 Oct 5;267(28):20033–20038. [PubMed] [Google Scholar]
  2. Bar-Sagi D., Feramisco J. R. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science. 1986 Sep 5;233(4768):1061–1068. doi: 10.1126/science.3090687. [DOI] [PubMed] [Google Scholar]
  3. Barbacid M. ras genes. Annu Rev Biochem. 1987;56:779–827. doi: 10.1146/annurev.bi.56.070187.004023. [DOI] [PubMed] [Google Scholar]
  4. Bourne H. R., Sanders D. A., McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 1990 Nov 8;348(6297):125–132. doi: 10.1038/348125a0. [DOI] [PubMed] [Google Scholar]
  5. Bretscher A. Microfilament structure and function in the cortical cytoskeleton. Annu Rev Cell Biol. 1991;7:337–374. doi: 10.1146/annurev.cb.07.110191.002005. [DOI] [PubMed] [Google Scholar]
  6. Chardin P. Small GTP-binding proteins of the ras family: a conserved functional mechanism? Cancer Cells. 1991 Apr;3(4):117–126. [PubMed] [Google Scholar]
  7. Cox A. D., Hisaka M. M., Buss J. E., Der C. J. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol Cell Biol. 1992 Jun;12(6):2606–2615. doi: 10.1128/mcb.12.6.2606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Crowell P. L., Chang R. R., Ren Z. B., Elson C. E., Gould M. N. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem. 1991 Sep 15;266(26):17679–17685. [PubMed] [Google Scholar]
  9. Downward J. Signal transduction. Rac and Rho in tune. Nature. 1992 Sep 24;359(6393):273–274. doi: 10.1038/359273a0. [DOI] [PubMed] [Google Scholar]
  10. Farnsworth C. C., Wolda S. L., Gelb M. H., Glomset J. A. Human lamin B contains a farnesylated cysteine residue. J Biol Chem. 1989 Dec 5;264(34):20422–20429. [PMC free article] [PubMed] [Google Scholar]
  11. Fujita H., Suzuki H., Kuzumaki N., Müllauer L., Ogiso Y., Oda A., Ebisawa K., Sakurai T., Nonomura Y., Kijimoto-Ochiai S. A specific protein, p92, detected in flat revertants derived from NIH/3T3 transformed by human activated c-Ha-ras oncogene. Exp Cell Res. 1990 Jan;186(1):115–121. doi: 10.1016/0014-4827(90)90217-x. [DOI] [PubMed] [Google Scholar]
  12. Garcia A. M., Rowell C., Ackermann K., Kowalczyk J. J., Lewis M. D. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem. 1993 Sep 5;268(25):18415–18418. [PubMed] [Google Scholar]
  13. Georges R. N., Mukhopadhyay T., Zhang Y., Yen N., Roth J. A. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 1993 Apr 15;53(8):1743–1746. [PubMed] [Google Scholar]
  14. Gibbs J. B. Ras C-terminal processing enzymes--new drug targets? Cell. 1991 Apr 5;65(1):1–4. doi: 10.1016/0092-8674(91)90352-y. [DOI] [PubMed] [Google Scholar]
  15. Gibbs J. B., Schaber M. D., Schofield T. L., Scolnick E. M., Sigal I. S. Xenopus oocyte germinal-vesicle breakdown induced by [Val12]Ras is inhibited by a cytosol-localized Ras mutant. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6630–6634. doi: 10.1073/pnas.86.17.6630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Graham S. L., deSolms S. J., Giuliani E. A., Kohl N. E., Mosser S. D., Oliff A. I., Pompliano D. L., Rands E., Breslin M. J., Deana A. A. Pseudopeptide inhibitors of Ras farnesyl-protein transferase. J Med Chem. 1994 Mar 18;37(6):725–732. doi: 10.1021/jm00032a004. [DOI] [PubMed] [Google Scholar]
  17. Haag J. D., Lindstrom M. J., Gould M. N. Limonene-induced regression of mammary carcinomas. Cancer Res. 1992 Jul 15;52(14):4021–4026. [PubMed] [Google Scholar]
  18. Hall A. Ras-related GTPases and the cytoskeleton. Mol Biol Cell. 1992 May;3(5):475–479. doi: 10.1091/mbc.3.5.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. He B., Chen P., Chen S. Y., Vancura K. L., Michaelis S., Powers S. RAM2, an essential gene of yeast, and RAM1 encode the two polypeptide components of the farnesyltransferase that prenylates a-factor and Ras proteins. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11373–11377. doi: 10.1073/pnas.88.24.11373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ingber D. E. Cellular tensegrity: defining new rules of biological design that govern the cytoskeleton. J Cell Sci. 1993 Mar;104(Pt 3):613–627. doi: 10.1242/jcs.104.3.613. [DOI] [PubMed] [Google Scholar]
  21. James G. L., Goldstein J. L., Brown M. S., Rawson T. E., Somers T. C., McDowell R. S., Crowley C. W., Lucas B. K., Levinson A. D., Marsters J. C., Jr Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science. 1993 Jun 25;260(5116):1937–1942. doi: 10.1126/science.8316834. [DOI] [PubMed] [Google Scholar]
  22. Johnston C., Morris J., Hall A. The role of Ras in signal transduction. Biochem Soc Trans. 1991 Apr;19(2):296–299. doi: 10.1042/bst0190296. [DOI] [PubMed] [Google Scholar]
  23. Kato K., Cox A. D., Hisaka M. M., Graham S. M., Buss J. E., Der C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6403–6407. doi: 10.1073/pnas.89.14.6403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Khosravi-Far R., Cox A. D., Kato K., Der C. J. Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ. 1992 Jul;3(7):461–469. [PubMed] [Google Scholar]
  25. Kim C. M., Goldstein J. L., Brown M. S. cDNA cloning of MEV, a mutant protein that facilitates cellular uptake of mevalonate, and identification of the point mutation responsible for its gain of function. J Biol Chem. 1992 Nov 15;267(32):23113–23121. [PubMed] [Google Scholar]
  26. Kinsella B. T., Erdman R. A., Maltese W. A. Carboxyl-terminal isoprenylation of ras-related GTP-binding proteins encoded by rac1, rac2, and ralA. J Biol Chem. 1991 May 25;266(15):9786–9794. [PubMed] [Google Scholar]
  27. Kohl N. E., Mosser S. D., deSolms S. J., Giuliani E. A., Pompliano D. L., Graham S. L., Smith R. L., Scolnick E. M., Oliff A., Gibbs J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 1993 Jun 25;260(5116):1934–1937. doi: 10.1126/science.8316833. [DOI] [PubMed] [Google Scholar]
  28. Maltese W. A. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 1990 Dec;4(15):3319–3328. doi: 10.1096/fasebj.4.15.2123808. [DOI] [PubMed] [Google Scholar]
  29. Moores S. L., Schaber M. D., Mosser S. D., Rands E., O'Hara M. B., Garsky V. M., Marshall M. S., Pompliano D. L., Gibbs J. B. Sequence dependence of protein isoprenylation. J Biol Chem. 1991 Aug 5;266(22):14603–14610. [PubMed] [Google Scholar]
  30. Müllauer L., Fujita H., Ishizaki A., Kuzumaki N. Tumor-suppressive function of mutated gelsolin in ras-transformed cells. Oncogene. 1993 Sep;8(9):2531–2536. [PubMed] [Google Scholar]
  31. Pompliano D. L., Rands E., Schaber M. D., Mosser S. D., Anthony N. J., Gibbs J. B. Steady-state kinetic mechanism of Ras farnesyl:protein transferase. Biochemistry. 1992 Apr 21;31(15):3800–3807. doi: 10.1021/bi00130a010. [DOI] [PubMed] [Google Scholar]
  32. Prasad G. L., Fuldner R. A., Cooper H. L. Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7039–7043. doi: 10.1073/pnas.90.15.7039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Prendergast G. C., Gibbs J. B. Pathways of Ras function: connections to the actin cytoskeleton. Adv Cancer Res. 1993;62:19–64. doi: 10.1016/s0065-230x(08)60314-0. [DOI] [PubMed] [Google Scholar]
  34. Prendergast G. C., Ziff E. B. Mbh 1: a novel gelsolin/severin-related protein which binds actin in vitro and exhibits nuclear localization in vivo. EMBO J. 1991 Apr;10(4):757–766. doi: 10.1002/j.1460-2075.1991.tb08007.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ridley A. J., Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992 Aug 7;70(3):389–399. doi: 10.1016/0092-8674(92)90163-7. [DOI] [PubMed] [Google Scholar]
  36. Ridley A. J., Paterson H. F., Johnston C. L., Diekmann D., Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992 Aug 7;70(3):401–410. doi: 10.1016/0092-8674(92)90164-8. [DOI] [PubMed] [Google Scholar]
  37. Seabra M. C., Reiss Y., Casey P. J., Brown M. S., Goldstein J. L. Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell. 1991 May 3;65(3):429–434. doi: 10.1016/0092-8674(91)90460-g. [DOI] [PubMed] [Google Scholar]
  38. Seigel G. M., Notter M. F. Differentiation of Y79 retinoblastoma cells induced by succinylated concanavalin A. Cell Growth Differ. 1993 Jan;4(1):1–7. [PubMed] [Google Scholar]
  39. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993 Apr 2;260(5104):85–88. doi: 10.1126/science.8465203. [DOI] [PubMed] [Google Scholar]
  40. Small J. V. The actin cytoskeleton. Electron Microsc Rev. 1988;1(1):155–174. doi: 10.1016/s0892-0354(98)90010-7. [DOI] [PubMed] [Google Scholar]
  41. Smith M. R., DeGudicibus S. J., Stacey D. W. Requirement for c-ras proteins during viral oncogene transformation. Nature. 1986 Apr 10;320(6062):540–543. doi: 10.1038/320540a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Trueblood C. E., Ohya Y., Rine J. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae. Mol Cell Biol. 1993 Jul;13(7):4260–4275. doi: 10.1128/mcb.13.7.4260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Ulsh L. S., Shih T. Y. Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs. Mol Cell Biol. 1984 Aug;4(8):1647–1652. doi: 10.1128/mcb.4.8.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zachary I., Rozengurt E. Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell. 1992 Dec 11;71(6):891–894. doi: 10.1016/0092-8674(92)90385-p. [DOI] [PubMed] [Google Scholar]

Articles from Molecular and Cellular Biology are provided here courtesy of Taylor & Francis

RESOURCES